Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;11(1):524.
doi: 10.1186/s11671-016-1698-9. Epub 2016 Nov 25.

Chitosan Nanolayered Cisplatin-Loaded Lipid Nanoparticles for Enhanced Anticancer Efficacy in Cervical Cancer

Jing-Yi Wang  1 , Yu Wang  2 , Xia Meng  3
Affiliations

Chitosan Nanolayered Cisplatin-Loaded Lipid Nanoparticles for Enhanced Anticancer Efficacy in Cervical Cancer

Jing-Yi Wang et al. Nanoscale Res Lett. 2016 Dec.

Abstract

In this study, cisplatin (CDDP)-loaded chitosan-coated solid lipid nanoparticles (SLN) was successfully formulated to treat HeLa cervical carcinoma. The formulation nanoparticles were nanosized and exhibited a controlled release of drug in physiological conditions. The blank nanoparticles exhibited an excellent biocompatibility profile indicating its suitability for cancer targeting. The incorporation of CDDP in SLN remarkably increased the cancer cell death as evident from the MTT assay. Importantly, CDDP-loaded chitosan-coated SLN (CChSLN) significantly (P < 0.05) decreased the viability of cancer cells even at low concentration. The higher cytotoxicity potential of CChSLN was attributed to the higher cellular uptake as well as the sustained drug release manner in comparison with CSLN. Consistent with the cytotoxicity assay, CChSLN showed the lowest IC50 value of 0.6125 μg/ml while CSLN presented 1.156 μg/ml. CChSLN showed a significantly higher apoptosis in cancer cells compared to that of CSLN and CDDP, which is attributed to the better internalization of nanocarriers and controlled release of anticancer drugs in the intracellular environment. Our findings suggest that this new formulation could be a promising alternative for the treatment of cervical cancers. These findings are encouraging us to continue our research, with a more extended investigation of cellular response in real time and in animal models.

Keywords: Antitumor efficacy; Cervical cancers; Chitosan; Cisplatin; Solid lipid nanoparticles.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Graphical presentation of the preparation of cisplatin-loaded chitosan-coated solid lipid nanoparticles
Fig. 2
Fig. 2
Particle size distribution of CSLN and CChSLN. The particle size of nanoparticles was measured by dynamic light scattering (DLS) technique
Fig. 3
Fig. 3
In vitro drug release profile of CSLN and CChSLN. The release study was performed in phosphate-buffered saline (PBS) at 37 °C for 72 h
Fig. 4
Fig. 4
In vitro cellular uptake of CSLN and CChSLN in HeLa cancer cells. Rhodamine B was used as a fluorescent probe
Fig. 5
Fig. 5
Biocompatibility analysis of blank SLN and chitosan-coated SLN in HeLa cervical cancer cells
Fig. 6
Fig. 6
Cytotoxicity potential of CDDP, CSLN, and CChSLN in HeLa cervical cancer cells. The cytotoxicity of formulations was analyzed by MTT assay
Fig. 7
Fig. 7
IC50 value of CDDP, CSLN, and CChSLN in HeLa cervical cancer cells
Fig. 8
Fig. 8
Morphological analysis of cancer cells after treatment with CDDP, CSLN, and CChSLN
Fig. 9
Fig. 9
The apoptosis analysis of formulations in cancer cells. The apoptosis assay was carried out by Annexin V/PI staining and determined by flow cytometer
See this image and copyright information in PMC

References

    1. IARC. Monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses, vol. 90. http://monographs.iarc.fr/. Accessed 10 May 2016.
    1. WHO (World Health Organization). Human papillomaviruses. http://www.w0ho.int/vaccine_research/diseases/viral_cancers/en/index3.html. Accessed 10 May 2016.
    1. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trialresults. Vaccine. 2008;26:K53–K61. doi: 10.1016/j.vaccine.2008.06.002. - DOI - PMC - PubMed
    1. Ma Y, Huang L, Song C, Zeng X, Liu G, Mei L. Nanoparticleformulation of poly(ε-caprolactone-co-lactide)-d-α-tocopheryl polyethyleneglycol 1000 succinate random copolymer for cervical cancer treatment. Polymer. 2010;51:5952–5959. doi: 10.1016/j.polymer.2010.10.029. - DOI
    1. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence ofhigh risk human papillomavirus (HPV) as indicator of high grade cervicalsquamous intraepithelial lesions in young women: population basedprospective follow up study. BMJ. 2002;325:572. doi: 10.1136/bmj.325.7364.572. - DOI - PMC - PubMed

LinkOut - more resources